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Background/aim: High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment
strategy for multiple myeloma (MM) patients who are eligible for it. The recommended dose of CD34+ hematopoietic progenitor cells
(HPCs) for adequate engraftment is above 2 × 106/kg. The aim of this study was to evaluate the relationship between the dose of CD34+
HPCs and survival in MM patients who underwent AHSCT at a tertiary care center.
Materials and methods: Enrolled in this study were 271 MM patients who underwent AHSCT between 2003 and 2019. Clinical
characteristics of the patients, disease status pre-AHSCT, reinfused CD34+ cell doses, and neutrophil and platelet engraftment days were
recorded, retrospectively. The patients were divided into 2 groups according to whether the dose of reinfused CD 34+ HPCs was <5 ×
106/kg or ≥5 × 106/kg. The groups were compared in terms of engraftment and overall survival (OS) times.
Results: The median age of the patients was 54.8 (33–76) years. The median dose of infused CD34+ HPCs was 5.94 × 106/kg (1.47–59.5
× 106/kg). The median follow-up period was 54 months (4–211). The median OS of the patients was 103 months (11–144). The median
neutrophil and platelet engraftment time was 10 (8–24) and 11 (7–40) days. Doses of <5 × 106/kg and ≥5 × 106/kg CD34+ HPC were
reinfused in 38.1% and 61.9% of the patients, respectively. There was a negative significant correlation between the reinfused CD34+
cell level and neutrophil/platelet engraftment times (r = –0.32, P < 0.001; r = –0.27, P < 0.001, respectively). The median OS times were
observed as 103 months (11–144) and 145 months (123–166) for patients who had been administered <5 × 106/kg and ≥5 × 106/kg of
CD34+ HPCs, respectively (P = 0.009).
Conclusion: The increased amount of CD34+ autologous hematopoietic stem cell dose after high dose melphalan chemotherapy in MM
patients shortened the platelet and neutrophil engraftment time and increased OS. Early platelet engraftment and administration of a
CD34+ HPC count that is ≥5 × 106/kg can be considered as predictors of better survival in patients.
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1. Introduction
Autologous hematopoietic stem cell transplantation
(AHSCT) in eligible multiple myeloma (MM)
patients is currently a standard treatment modality
[1]. The amount of CD34+ hematopoietic progenitor
cells (HPCs) that can be mobilized in AHSCT may
vary depending on the age, dose, and duration of
chemotherapies, and the bone marrow involvement
of the disease [2]. The increase in the amount of
reinfused stem cells reduces the risk of complications
and hospitalization by shortening the neutrophil and
platelet engraftment times [3,4]. Many studies have
been conducted to determine the appropriate amount
of stem cells to be administered. The infusion of CD34+

HPCs above 2 × 106/kg is usually the recommended
dose to prevent engraftment failure or late recovery
[5,6]. There are studies that have shown that
administering <5 × 106/kg of CD34+ HPCs prolongs
the engraftment time and, especially, adversely affects
platelet recovery [7]. The International Myeloma
Working Group (IMWG) recommends that an average
of 8 × 106/kg CD34+ should be given if mobilized, and
that the minimum administration target should be 4 ×
106/kg CD34+ progenitor cells [8].
In the present study, the association between CD34+
HPC level, and engraftment and survival time in MM
patients who underwent AHSCT at the Hacettepe
University Hematology Department was analyzed.
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2. Material and methods
2.1. Study population
This study included 271 MM patients who underwent
AHSCT at the Hacettepe University Department of
Hematology between 2003 and 2019. All of the data were
analyzed retrospectively. As a standard of care/action
of the hospitals of Hacettepe Medical School, all of the
ethical considerations were strictly followed, all of the
patients gave informed consent for the procedure at the
time of hospitalization, and before the administration of
chemotherapy and other relevant diagnostic/therapeutic
procedures, in accordance with the Declaration of Helsinki.
2.2. Mobilization of peripheral blood stem cells
All of the patients received 4 ± 2 courses of bortezomibdexamethasone,
bortezomib-cyclophosphamidedexamethasone, or vincristine-adriamycin-dexamethasone
chemotherapy during the prebortezomib era, and 28
day schedules for induction chemotherapy for MM [9].
Granulocyte colony stimulating factor was administered
at a dose of 10 µg/kg for a minimum of 5 days. When the
CD34 level ≥20 µL, the patients underwent leukapheresis.
Additional apheresis was performed with Plerixaphor in 24
patients, due to the insufficient amount of stem cells had
been collected.
2.3. Response
The neutrophil engraftment time was accepted as the
first of 3 consecutive days, with an observed absolute
neutrophil count of ≥0.5 × 109/L. The platelet engraftment
time was accepted as the first of 3 consecutive days with a
platelet count that measured ≥20 × 109/L, without the need
for replacement.
2.4. Endpoints
The primary aim of this study was to demonstrate the
correlation between the CD34+ HPC level, and the platelet
and neutrophil engraftment times. The secondary aim was
to investigate the effect of the infused CD34+ HPC count at
the 5 × 106/kg cut-off value on long-term overall survival
(OS).
2.5. Statistics
Patient and transplant characteristics were summarized
using descriptive statistics. The chi-square test was used
for the statistical comparisons between the disease groups.
The independent sample t test was used the compare the
parameters if the data were normally distributed, while
the Mann-Whitney U test was used for the nonnormally
distributed data. Univariate linear regression analysis was
performed for each potential risk variable. As independent
variables, baseline demographic and clinical characteristics
at P < 0.1 via univariate analysis were included into
the multivariate regression analysis using the stepwise
model to predict engraftment and survival. During the
multivariate regression analysis, tolerance and variance
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inflation factor values of collinearity statistics were taken
into consideration to avoid potential strong correlation
among the independent variables.
All of the patients were followed longitudinally until
death or last follow-up. Kaplan Meier curves were used
to estimate the OS calculated from the time of diagnosis
date until death, or to the last follow-up evaluation. The
relationship between the platelet/neutrophil engraftment
time and CD34+ HPC dose was evaluated using Spearmen
correlation analysis. All statistical analyses were performed
using IBM SPSS Statistics for Windows 25.0 (IBM Corp.,
Armonk, NY, USA).
3. Results
3.1. Patients characteristics
The median age of the patients included in the study was
54.8 (33–76) years. The median amount of infused CD34+
HPCs was 5.94 × 106/kg (1.47–59.5 × 106/kg). When the
administered CD34+ HPC cut-off value was taken as 5
× 106/kg, 103 patients had stem cell infusion below this
cut-off level, while 168 patients were above this level. The
comparison of the clinical baseline characteristics of both
groups are given in Table 1.
3.2. Hematologic recovery
The median platelet engraftment time was 11 days (7–40)
and the median neutrophil engraftment time was 10 days
(8–24). Engraftment failure was not observed in any of
the patients. When the neutrophil and platelet recoveries
were evaluated, there was a significant negative correlation
between the engraftment time and administered CD34+
HPCs in both groups (Figure 1).
3.3. Overall survival
The median follow-up period of the patients was 54 months
(4–211). A total of 60 patients, who had been followed-up,
died during this period. Of these patients, 61% had died
due to infectious causes. The 100-day transplantationrelated mortality was 1.1% (3 patients), mainly due to the
viral infection (H1N1)-related mortality.
The median OS time was 103 months (11–144) for
patients who were administered <5 × 106/kg of CD34+
HPCs and 145 months (123–166) for patients who were
administered ≥5 × 106/kg of CD34+ HPCs (P = 0.009)
(Figure 2). When evaluated using multivariate analysis, the
CD34+ HPC level of <5 × 106/kg, and lambda subtype and
platelet engraftment time above 10 days were observed to
have a poor prognostic effect on OS (Table 2).
4. Discussion
MM constitutes about 10% of hematologic malignancies
and approximately 1% of all malignancies [10]. Currently,
the standard treatment is high-dose melphalan with
AHSCT for suitable patients [1]. The amount of CD34+
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Table 1. Patient characteristics based on reinfused CD34+
HPC levels. CR: complete remission, VGPR: very good partial
remission, PR: partial remission, F: female, M: male, Ig:
immunoglobulin.
Reinfused CD34+
HPC dose (×106/kg)
<5

≥5

n

103

168

Sex (F/M)

31/72

70/98

0.037

Age

54.8

54.7

0.86

Type of MM

P value

0.163

IgA kappa

17

24

IgA lambda

10

11

IgG kappa

30

66

IgG lambda

25

24

IgD kappa

1

1

IgD lambda

1

3

Kappa light chain

8

26

Lambda light chain

11

13

Disease status (pre-AHSCT)

0.17

CR

9

9

VGPR

11

31

PR

67

97

Refractory

12

27

VAD

70

94

VD

15

33

VCD

18

41

Type of chemotherapy

0.14

VD:
bortezomib-dexamethasone,
cyclophosphamide-dexamethasone,
adriamycin-dexamethasone.

VCD:
VAD:

bortezomibvincristine-

HPCs mobilized for reinfusion for AHSCT may vary
depending on the type and duration of chemotherapy, age,
disease status, and radiotherapy history of the individual.
Collection of CD34+ HPCs below 1 × 106/kg is identified
as mobilization failure, while the collection of CD34+
HPCs between 1–5 × 106/kg is identified as inadequate
mobilization [11]. In a previous study, it was shown that
adequate mobilization was achieved in 94% of patients
receiving treatment for less than 2 years and in 28% of
patients receiving treatment for a longer period of time [5].
It is known that the high amount of reinfused CD34+
HPCs reduces hospitalization by shortening the
engraftment time [12,13]. However, although there is no
clear consensus on the border CD34+ level, it has been

stated by the MM IGWS group that the administration
of CD34+ HPCs above 4 × 106/kg will be sufficient for a
healthy engraftment period [14]. In many studies, it was
found that a CD34 dose of 2.5 × 106/kg was sufficient for
engraftment, while administering stem cells ≥5 × 106/kg
has been shown to shorten the engraftment time. A limited
number of studies have shown that administering CD34+
HPCs at a dose of ≥11 × 106/kg prolonged hospitalization
time by causing fever and engraftment syndrome. In
one study, engraftment was achieved on day 21 in 63%
of the patients with 2.5–5 × 106/kg of the CD34+ stem
cells collected, while a platelet value of ≥50 × 109/L was
obtained in 93% of the patients administered above 5 ×
106/kg of CD34+ HPCs. In the present study, the median
platelet engraftment time was found as 10 days in all of
the patients who had been engrafted adequately. In this
study, a shorter platelet engraftment time was observed as
an independent predictive factor for OS.
It was shown that the neutrophil engraftment time
was 18, 15, and 13 days in 95% of the patients receiving
CD34+ HPCs at cut-off values of 2.5, 5, and 7.5 × 106/kg,
respectively [15].
In a different study, it was shown that the administration
of 2.5–5 × 106/kg or 5 × 106/kg CD34+ HPCs did not
provide any difference in survival (P = 0.186) [5]. In
the current study, a significant negative correlation was
observed between the neutrophil engraftment time and
the number of CD34+ HPCs. When multivariate analysis
was performed, it was shown that it was not predictive of
OS.
Additionally, the multivariate analysis for investigating
the predictive factors for survival showed that a low CD34
level, platelet engraftment time of ≥10 days, and lambda
light chain types were poor prognostic factors. There
have been clinical studies showing that patients with high
serum lambda levels had low survival rates. According
to one clinical study, the 5-year survival rate was 63% in
patients with free lambda levels below the median value
and 37% in patients above the median value (hazard ratio
= 2.44, 95% CI: 1.50–3.97, P = 0.001) [16]. The lambda
subtype was shown to be a poor prognostic factor in the
study, but no analysis in accordance with this finding was
performed for lambda light chain levels [16].
In the present study, the CD34+ HPC dose above the 5
× 106/kg threshold was demonstrated to positively impact
OS. This was attributed to the fact that the mobilized CD34+
HPC levels of the patients were possibly associated with
the bone marrow reserves, and that patients with low bone
marrow reserves were somewhat susceptible to infection.
In this study, 61% of the deceased patients had died due
to infectious causes, mainly comprising encapsulated
bacterial and viral infections, such as influenza.
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Figure 1. The infused CD34+ HPC dose and the correlation graphs of neutrophil and
platelet engraftment times (r = –0.32, P < 0.001; r = –0.27, P < 0.001, respectively).

Figure 2. The Kaplan-Meier survival graph showing the difference in OS in patients with infusion of
above and below 5 × 106/kg CD34+ HPC/kg (P = 0.009).
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Table 2. Hazard ratio (HR) for clinical factors in the OS of MM patients who underwent AHSCT.
Univariate

Multivariate

OS
HR

p

HR

P value

Age (<65, ≥65)

1.2 (1.1-1.4)

0.44

Sex (F/M)

0.14

0.51

IgA

1.1 (0.9–1.4)

0.55

IgG

1.1 (0.9–2.13)

0.42

IgD

1.5 (0.8–2.4)

0.053

2.8 (0.5–15)

0.22

Type of light chain (kappa/lambda)

1.12 (0.97–1.27)

0.056

0.6

0.039

2

1.18 (0.9–1.4)

0.67

3

1.24 (1–1.4)

0.51

1.5 (1.2–1.9)

0.52

0.5 (0.2–2.5)

0.529

1.3 (1–1.7)

0.88

Reinfused CD34 HPC (<5 or ≥5 × 10 /kg)

1.3 (1.2–1.4)

<0.001

1 (1.4–5.6)

0.021

Neutrophil engraftment time (<10, ≥10 days)

1.1 (0.9–1.2)

0.03

0,59

0.48

Platelet engraftment time (<10, ≥10 days)

1.11 (0.83–1.38)

0.027

0,9

0.029

Type of heavy chain

ISS score (reference score1)

Disease Status pre-AHSCT (reference CR)
PR
Refracory
+

6

5. Conclusion
The increased dose of CD34+ autologous hematopoietic
stem cells after high-dose melphalan chemotherapy in
MM patients shortened the platelet and neutrophil
engraftment time and increased OS. Early platelet
engraftment and the administration of a CD34+
HPC count that is ≥5 × 106/ kg can be considered as
predictors of a better survival in patients. However,
further larger multicentered studies are needed to
better elucidate the ideal CD34+ HPC dose affecting
OS in MM.

Acknowledgments/Disclaimers/Conflict of interest
The authors declare they have no conflicts of interest.
Informed consent
As a standard of care/action of the hospitals of Hacettepe
Medical School, all of the ethical considerations were
strictly followed, all of the patients gave informed consent
for the procedure at the time of hospitalization and before
the administration of chemotherapy and other relevant
diagnostic/therapeutic procedures were followed in
accordance with the Declaration of Helsinki.

References
1.

Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE et al.
Medical Research Council Adult Leukaemia Working P: Highdose chemotherapy with hematopoietic stem-cell rescue for
multiple myeloma. New England Journal of Medicine 2003;
348 (19): 1875-1883. doi:10.1056/NEJMoa022340

2.

Şahin U, Demirer T. Current strategies for the management of
autologous peripheral blood stem cell mobilization failures in
patients with multiple myeloma. Journal of Clinical Apheresis
2018; 33 (3): 357-370. doi: 10.1002/jca.21591

3.

Stiff PJ, Micallef I, Nademanee AP, Stadtmauer EA, Maziarz RT
et al. Transplanted CD34(+) cell dose is associated with longterm platelet count recovery following autologous peripheral
blood stem cell transplant in patients with non-Hodgkin
lymphoma or multiple myeloma. Biology of Blood Marrow
Transplantation 2011; 17 (8): 1146-1153.doi: 10.1016/j.
bbmt.2010.11.021

1855

ALADAĞ et al. / Turk J Med Sci
4.

Ungerstedt JS, Watz E, Uttervall K, Johansson BM, Wahlin
BE et al. Autologous hematopoietic stem cell transplantation
in multiple myeloma and lymphoma: an analysis of factors
influencing stem cell collection and hematological recovery.
Medical Oncology 2012; 29 (3): 2191-2199. doi:10.1007/
s12032-011-0029-3

5.

Jillella AP, Ustun C. What is the optimum number of CD34+
peripheral blood stem cells for an autologous transplant? Stem
Cells and Developments 2004; 13 (6): 598-606.doi:10.1089/
scd.2004.13.598

6.

Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M et
al. Poor mobilization of hematopoietic stem cells-definitions,
incidence, risk factors, and impact on outcome of autologous
transplantation. Biology of Blood and Marrow Transplantation
2010; 16 (4): 490-499. doi:10.1016/j.bbmt.2009.11.012

7.

Solmaz Medeni Ş, Türkyılmaz D, Acar C, Sevindik OG, Yüksel
Fet al. Does Reinfusion of Stem Cell Products on Multiple Days
Affect Engraftment? Turkish Journalof Hematology 2018; 35
(4): 271-276.doi: 10.4274/tjh.2018.0071

8.

Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A,
Bensinger W et al. International myeloma working group
(IMWG) consensus statement and guidelines regarding the
current status of stem cell collection and high-dose therapy
for multiple myeloma and the role of plerixafor (AMD 3100).
Leukemia 2009; 23 (10): 1904-1912.doi: 10.1038/leu.2009.127

9.

Multiple myeloma: 2018 update on diagnosis, risk-stratification,
and management. American journal of hematology 2018; 93
(8): 981-1114.doi:10.1002/ajh.25117

10.

Bird JM, Owen RG, D’Sa S, Snowden JA, Pratt G et al.
Guidelines for the diagnosis and management of multiple
myeloma 2011. British Journal of Haematology 2011; 154 (1):
32-75.doi:10.1111/j.1365-2141.2011.08573.x

1856

11.

Gertz MA. Current status of stem cell mobilization.
British Journal of Haematology 2010; 150(6):647-662.doi:
10.1111/j.1365-2141.2010.08313.x

12.

Lanza F, Campioni DC, Hellmann A, Milone G, WahlinA et
al. Individual quality assessment of autografting by probability
estimation for clinical endpoints: a prospective validation
study from the European group for blood and marrow
transplantation. Biology of Bloodand Marrow Transplantation
2013; 19 (12): 1670-1676.doi:10.1016/j.bbmt.2013.08.005

13.

Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic
relevance of CD34 cell dose in blood cell transplantation for
cancer therapy. Journal of clinical oncology: official journal of
the American Society of Clinical Oncology 2000; 18 (6): 13601377.doi:10.1200/JCO.2000.18.6.1360

14.

Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty
M. Current status of autologous stem cell transplantation for
multiple myeloma. Blood Cancer Journal 2019; 9 (4): 44.doi:
10.1038/s41408-019-0205-9

15.

Weaver CH, Hazelton B, Birch R, Palmer P, Allen C et al.
An analysis of engraftment kinetics as a function of the
CD34 content of peripheral blood progenitor cell collections
in 692 patients after the administration of myeloablative
chemotherapy. Blood 1995; 86 (10): 3961-3969.

16.

García de Veas Silva JL, Bermudo Guitarte C, Menendez
Valladares P, Rojas Noboa JC, Kestler K et al. Prognostic
Value of Serum Free Light Chains Measurements in Multiple
Myeloma Patients. PLoS One 2016; 11 (11): e0166841. doi:
10.1371/journal.pone.0166841

